Prakash Reddy, MD
Sleep Medicine · Indialantic, FLNPI 1528043163
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,486 of the $12,022 with a category attached, or 70.6%. 28 manufacturers reported payments, led by Sunovion Pharmaceuticals Inc. at 28.0% of the total.
Across 374 payments — averaging $32.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$3K
- GSK$2K
- Harmony Biosciences LLC$2K
- Boehringer Ingelheim$1K
- AstraZeneca$987
- Axsome Therapeutics, Inc.$572
- plus $2K from 22 others
What the payments were for
- Speaking & faculty fees$2,28019%
- Travel & lodging$9568%
- Food & beverage$8,48671%
- Education$3002%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 8 | $3,364 |
| GSK | 109 | $2,162 |
| Harmony Biosciences LLC | 43 | $2,043 |
| Boehringer Ingelheim | 58 | $1,097 |
| AstraZeneca | 53 | $987 |
| Axsome Therapeutics, Inc. | 26 | $572 |
| Electromed, Inc. | 25 | $489 |
| Baxter Healthcare | 5 | $131 |
| Inspire Medical Systems, Inc. | 2 | $129 |
| Novo Nordisk | 1 | $124 |
| Fisher & Paykel Healthcare Inc | 4 | $113 |
| Philips North America LLC | 5 | $113 |
| Genentech USA, Inc. | 2 | $80 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $69 |
| Jazz Pharmaceuticals Inc. | 3 | $68 |
| Mallinckrodt Hospital Products Inc. | 3 | $66 |
| Grifols USA, LLC | 5 | $65 |
| Inogen, Inc. | 3 | $57 |
| Merck | 3 | $48 |
| Pulmonx Corporation | 2 | $46 |
| Lilly USA, LLC | 2 | $39 |
| Mylan Specialty L.p. | 2 | $34 |
| Johnson & Johnson | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| ZOLL Respicardia, Inc. | 1 | $20 |
| Resmed Corp | 1 | $19 |
| Amgen | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LONHALA MAGNAIR$3,214
- Wakix$250
- NUCALA$224
- TEZSPIRE$125
- Inspire$106
How this compares
$12,022 in reported general payments places this provider in the 80th percentile of 77 sleep medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $144,963 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 109 | $134,299 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $34,888 |
| Spiriva RespimatTiotropium Bromide | 24 | $30,946 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $21,817 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $20,657 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 148 | $8,446 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 14 | $5,965 |
| Ventolin HfaAlbuterol Sulfate | 37 | $4,013 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $3,807 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 14 | $1,608 |
| Fluticasone Propionate | 73 | $1,513 |
| Modafinil | 42 | $1,278 |
| Armodafinil | 13 | $722 |
| Doxycycline Hyclate | 51 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $2,162 | $189,844183 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $1,097 | $175,90935 claims |
| AstraZenecaBreztri Aerosphere | $987 | $21,81716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 sleep medicine providers in Florida.
Other sleep medicine in Indialantic
- Jeremy McConnellBradenton$615K
- Edward MezerhaneMiami$537K
- Shane DrahosWinter Garden$317K
- Kunal AgarwalSarasota$153K
- Camilo RuizFort Lauderdale$136K
- Sergio JaramilloMiami$32K
- Carlos Ramirez MejiaMiami$25K
- Luis OrtizSt Petersburg$24K
- Harneet WaliaMiami$19K
- Radhika VermaOrange City$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.